Success Story: Advancing Epigenetic Cancer Research and Biotechnology: NIW Approval in 64 Days for a Molecular Biochemistry Researcher with Premium Processing Service
Client’s Testimonial:
"Thank you very much for all of your help throughout my EB-2 NIW petition process. I truly appreciate your team's professionalism and support."
On July 9th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Research Fellow in the Field of Molecular Biochemistry (Approval Notice).
General Field: Molecular Biochemistry
Position at the Time of Case Filing: Postdoctoral Research Fellow
Country of Origin: Taiwan
State of Residence at the Time of Filing: New York
Approval Notice Date: July 9th, 2026
Processing Time: 2 months, 3 days (Premium Processing Requested)
Case Summary:
Obtaining a National Interest Waiver (NIW) requires demonstrating that the proposed research will benefit the United States beyond the interests of a single employer. We were pleased to help secure approval of this I-140 NIW petition in just 64 days through Premium Processing for a researcher whose work advances epigenetic cancer therapies and biotechnology innovation.
The client holds a Ph.D. in biomedical and veterinary sciences and specializes in molecular biochemistry. The client's proposed endeavor is to continue developing biochemical reconstitution, chromatin enzymology, and protein engineering approaches to study and modulate epigenetic enzyme control of chromatin and gene expression in order to advance precise epigenetic-based cancer therapies and biotechnology tools that improve human health and research innovation. At the time of filing, the client was preparing to continue research focused on epigenetic mechanisms underlying cancer biology while expanding biochemical platforms for studying chromatin enzymes. We demonstrated that this work possesses substantial merit and national importance because it supports the development of more precise cancer therapies while strengthening biotechnology capabilities that contribute to biomedical innovation, public health, and U.S. scientific leadership.
To establish that the client was well positioned to advance this endeavor, we presented evidence showing both a strong research foundation and growing recognition from the scientific community. Rather than relying solely on publication numbers, we demonstrated how the client's research had already enabled other laboratories to advance their own studies of chromatin regulation and cancer biology. We also emphasized that the client's work contributes valuable biochemical tools and mechanistic insights that can accelerate future discoveries in epigenetics and precision medicine.
The client's credentials included:
- 5 peer-reviewed journal articles, including 3 first-authored publications.
- Research published in highly regarded peer-reviewed journals within the field.
- Research methods adopted by independent laboratories studying chromatin regulation and cancer biology.
Beyond these credentials, we highlighted that independent researchers had implemented the client's biochemical methods to obtain full-length chromatin enzymes for cancer-related studies, illustrating that the work had practical value beyond the client's own research program. Rather than presenting publications as isolated achievements, we explained that other scientists were actively applying the client's methodologies to investigate chromatin regulation, leukemia, and other cancer-associated mechanisms. This independent implementation provided objective evidence that the client's research was already advancing ongoing work throughout the broader scientific community.
The petition further emphasized the originality and practical significance of the client's research by describing contributions to understanding epigenetic enzyme regulation, developing scalable biochemical platforms, and engineering experimental systems that enable more effective studies of chromatin biology. We explained that these advances support the long-term development of precision epigenetic therapies while also providing biotechnology tools that benefit cancer research and biomedical innovation more broadly.
After reviewing the totality of the evidence, USCIS concluded that the client satisfied the National Interest Waiver framework and approved the petition without any RFE. We congratulate the client on this well-deserved NIW approval and look forward to seeing future contributions to the field of molecular biochemistry.